Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.

The article presents a study which examined the influence of idelalisib on platelet aggregation and coagulation tests in patients with chronic lymphocytic leukaemia (CLL). In the study, the subjects took either ibrutinib or idelalisib based on their baseline characteristics, drug interactions, and side effects. Also cited is the use of the validated questionnaire for bleeding diathesis, the International Society on Thrombosis and Haemostasis bleeding assessment tool (ISTH BAT), in the study.